Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gyre TherapeuticsSTU:L9S 43 Days Payable is 30.99 as of Jun. 2026, which is 65% above its 10-year median of 18.78. GuruFocus rates STU:L9S with a GF Score™ of 43/100 and a GF Value™ of €7.95. The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, Gyre Therapeutics ranks worse than 85.23% on this metric.
The historical rank and industry rank for Gyre Therapeutics's Days Payable or its related term are showing as below:
STU:L9S'
s Days Payable Range Over the Past 10 Years
Min: 7.82 Med: 18.78 Max: 24.15
Current: 24.15
During the past 5 years, Gyre Therapeutics's highest Days Payable was 24.15. The lowest was 7.82. And the median was 18.78.
STU:L9S's Days Payable is ranked worse than 85.23% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs STU:L9S: 24.15
Gyre Therapeutics's Days Payable
increased
from Jun. 2025 (8.00) to Jun. 2026 (30.99).
It may suggest that Gyre Therapeuticsdelayed paying its suppliers.
The historical data trend for Gyre Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L9S vs OCS, RIGL, SGP: Days Payable Comparison
For the Biotechnology subindustry, Gyre Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gyre Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (STU:L9S) has a Days Payable of 30.99 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gyre Therapeutics and its competitors. This is 65% above median its historical median of 18.78. Over the past decade, Gyre Therapeutics' Days Payable has ranged from 7.82 to 24.15. According to the industry distribution chart, Gyre Therapeutics ranks #600 out of 704 companies in the Biotechnology industry, placing it in the top 85.2%.
Is Gyre Therapeutics' Days Payable too high?
Gyre Therapeutics' current Days Payable of 30.99 is 65% above median its 10-year median of 18.78. Over the past 10 years, this metric has ranged from a low of 7.82 to a high of 24.15. The Biotechnology industry median Days Payable is 112.72. Gyre Therapeutics' value of 30.99 is 72.5% below this industry median. Based on the distribution chart, Gyre Therapeutics ranks #600 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Days Payable compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #600 out of 704 companies for Days Payable. This places Gyre Therapeutics in the lower half of its industry. The industry median Days Payable is 112.72. Gyre Therapeutics' value of 30.99 is 72.5% below this benchmark. Historically, Gyre Therapeutics' own Days Payable has ranged from 7.82 to 24.15 over the past decade. While the company's 10-year median is 18.78 vs. the industry median of 112.72, Gyre Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Days Payable of 30.99 is 72.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Days Payable is 30.99, which is 65% above median its own 10-year median of 18.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Gyre Therapeutics (STU:L9S) has a current Days Payable of 30.99. The stock's GF Value™ is €7.95, compared to a current price of €5.75 — trading 27.7% below its estimated fair value. The current Days Payable is 30.99, which is 65% above median its 10-year median of 18.78 and 72.5% below the Biotechnology industry median of 112.72. Gyre Therapeutics' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gyre Therapeutics (STU:L9S), the current Days Payable is 30.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (STU:L9S) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of €5.75 is trading 27.7% below its estimated GF Value™ of €7.95.
Key valuation signals for STU:L9S:
Days Payable: 30.99 (65% above median its 10-year median of 18.78)
GF Value™: €7.95 vs. price of €5.75 (27.7% below fair value)
Industry Position: 72.5% below the Biotechnology median (#600 of 704)
No single metric tells the full story. See the STU:L9S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score
Get the complete analysis for STU:L9S
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L9S has been successfully added to your 
